MYCN and neuroblastoma: Even though pharmacologic mTOR inhibitors, such as rapamycin, are in clinical use in patients suffering from different cancers, including MYCN-amplified neuroblastoma, biomarkers predicting mTOR inhibitor sensitivity are largely lacking.